Adalta Ltd has released a press release.
Inhaled AD-214 passes first development milestone
Filed with ASX ·
6ix hasn’t read this filing yet.
Earlier from AdAlta
- AGM presentations & first iCAR-T data
- Second US patent for AD-214
- BTB funding transferred to AD-214 inhalation program
- New pre-clinical data presented at Boston conference
- Corporate overview and IRD Invest 2021 presentation
Later from AdAlta
- Voluntary Suspension
- Reinstatement to Quotation
- Entitlement Offer Booklet
- Presentation Conference Schedule - January 2022
- Presentation to Share Cafe Webinar
Follow AdAlta into a list and get an email when it puts out news.
Follow AdAlta